• Bright Minds Biosciences reported a net and comprehensive loss of CAD 10.46 million for the three months ended March 31, 2026, widening from CAD 2.95 million a year earlier.
• Basic and diluted loss per share deepened to CAD 1.09 from CAD 0.42 in the same quarter last year.
• For the six months ended March 31, 2026, net and comprehensive loss widened to CAD 18.02 million from CAD 2.9 million, while interest income rose to CAD 3.51 million from CAD 513,699.
• Cash and cash equivalents climbed to CAD 309.69 million as of March 31, 2026 from CAD 82.91 million at Sept. 30, 2025.
• Share capital increased to CAD 365.78 million from CAD 123.25 million, following CAD 243.25 million in gross proceeds from a public offering and CAD 13.94 million from at-the-market sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bright Minds Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-002801), on May 20, 2026, and is solely responsible for the information contained therein.